Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Mounjaro is the world's first sustained GIP/GLP-1 receptor agonist approved by the Ministry of Health, Labour and Welfare in 2023 as a new treatment for type 2 diabetes
Beyond their metabolic effects, GLP-1 RAs have demonstrated cardiovascular and renal benefits in large outcome trials, including reductions in major adverse cardiovascular events (MACE) and attenuation of albuminuria progression (517)
Follow these steps: 1
In the pivotal STEP-1 trial, participants taking Wegovy lost an average of 14.9% of their body weight over 68 weeks
US$ 28.53
US$ 28.11
US$ 20.82
:max_bytes(150000):strip_icc()/TAL-header-robin-raven-GLP1TRAVAS0726-f491f320c79f4d8eaa9aac27bbc26a5e.jpg)
US$ 20.74
